Your email has been successfully added to our mailing list.

×
0 -0.00733944954128441 -0.00733944954128441 -0.0137614678899083 -0.0533669724770642 -0.0642201834862385 -0.0807339449541283 -0.0821100917431192
Stock impact report

BiondVax universal flu vaccine candidate successful in mid-stage study; shares ahead 9% premarket [Seeking Alpha]

BiondVax Pharmaceuticals Ltd. - American Depositary Shares (BVXV) 
US:NASDAQ Investor Relations: biondvax.com/investors
Company Research Source: Seeking Alpha
Thinly traded nano cap BiondVax Pharmaceuticals (NASDAQ: BVXV ) is up   premarket on increased volume in response to its announcement of positive results from a Phase 2b clinical trial assessing universal flu vaccine candidate M-001. The study met both endpoints of safety and influenza-specific cellular immune responses. The company intends to advance M-001 into Phase 3 development. Now read: Aimmune Banks On Food Allergies, Study Expected To Show Positive Results » Show less Read more
Impact Snapshot
Event Time:
BVXV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for BVXV alerts
Opt-in for
BVXV alerts

from News Quantified
Opt-in for
BVXV alerts

from News Quantified